Drugs · acquisition-cost intelligence
NORLIQVA
amlodipine· ingredient amlodipineDihydropyridine derivatives· AMLODIPINE 1 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$3.21
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-27
Same-ingredient options by acquisition cost
Other amlodipine products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| AMLODIPINE BESYLATE 10 mg | $0.01136 | −$3.19 |
| AMLODIPINE BESYLATE 10 mg | $0.01545 | −$3.19 |
| Lotrel | $0.11766 | −$3.09 |
| Amlodipine and Benazepril Hydrochloride | $0.14444 | −$3.06 |
| Amlodipine and Olmesartan Medoxomil | $0.29530 | −$2.91 |
| Exforge | $0.48831 | −$2.72 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE and HYDROCHLOROTHIAZIDE | $1.23 | −$1.98 |
| Caduet | $1.41 | −$1.79 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.